Lemaitre Vascular (LMAT) Liabilities and Shareholders Equity (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $629.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 13.22% year-over-year to $629.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 31.0% YoY) and the FY2025 annual result came in at $615.7 million, up 11.58% from the prior year.
• Liabilities and Shareholders Equity improved to $629.5 million in Q1 2026 per LMAT's latest filing, from $615.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $629.5 million in Q1 2026 and bottomed at $292.5 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $354.0 million (2024), against an average of $420.5 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity climbed 4.34%; it then surged 59.13% in 2024.
• Tracing LMAT's Liabilities and Shareholders Equity over 5 years: stood at $310.5 million in 2022, then rose by 11.69% to $346.8 million in 2023, then surged by 59.13% to $551.8 million in 2024, then increased by 11.58% to $615.7 million in 2025, then increased by 2.25% to $629.5 million in 2026.
• Per Business Quant, the three latest LMAT Liabilities and Shareholders Equity figures stand at $629.5 million (Q1 2026), $615.7 million (Q4 2025), and $598.1 million (Q3 2025).

Peer Comparison